Pono Capital Two (NASDAQ:PTWO) versus Oncology Institute (NASDAQ:TOI) Financial Analysis

Pono Capital Two (NASDAQ:PTWO) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

60.8% of Pono Capital Two shares are owned by institutional investors. Comparatively, 36.9% of Oncology Institute shares are owned by institutional investors. 63.9% of Pono Capital Two shares are owned by company insiders. Comparatively, 13.1% of Oncology Institute shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Pono Capital Two and Oncology Institute’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pono Capital Two	N/A	-6.63%	0.73%
Oncology Institute	-24.56%	-80.46%	-28.14%

Earnings & Valuation

This table compares Pono Capital Two and Oncology Institute’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pono Capital Two	N/A	N/A	$340,000.00	N/A	N/A
Oncology Institute	$324.24 million	0.25	-$83.07 million	($0.92)	-1.16

Pono Capital Two has higher earnings, but lower revenue than Oncology Institute.

Volatility & Risk

Pono Capital Two has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Pono Capital Two and Oncology Institute, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pono Capital Two	0	0	0	0	N/A
Oncology Institute	0	0	1	0	3.00

Oncology Institute has a consensus target price of $2.25, suggesting a potential upside of 110.28%. Given Oncology Institute’s higher possible upside, analysts clearly believe Oncology Institute is more favorable than Pono Capital Two.

Summary

Pono Capital Two beats Oncology Institute on 6 of the 10 factors compared between the two stocks.

About Pono Capital Two

Pono Capital Two, Inc. does not have any significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Pono Capital Two, Inc. was incorporated in 2022 and is based in Honolulu, Hawaii.

About Oncology Institute

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.